GSK plc Website

GSK plc

LSE-GSK

Basic

  • Market Cap

    £65.43B

  • EV

    £78.5B

  • Shares Out

    4,078.06M

  • Revenue

    £30.74B

  • Employees

    70,212

Margins

  • Gross

    72.67%

  • EBITDA

    34.28%

  • Operating

    28.39%

  • Pre-Tax

    17.93%

  • Net

    14.59%

  • FCF

    20.64%

Returns (5Yr Avg)

  • ROA

    9.73%

  • ROTA

    -52.07%

  • ROE

    51.48%

  • ROCE

    15.6%

  • ROIC

    10.99%

Valuation (TTM)

  • P/E

  • P/B

  • EV/Sales

  • EV/EBITDA

  • P/FCF

  • EV/Gross Profit

Valuation (NTM)

  • Price Target

    £20.36

  • P/E

  • PEG

  • EV/Sales

  • EV/EBITDA

  • P/FCF

Financial Health

  • Cash

    £4,095M

  • Net Debt

    £13.68B

  • Debt/Equity

    1.34

  • EBIT/Interest

    12.93

Growth (CAGR)

  • Rev 3Yr

    0.63%

  • Rev 5Yr

    -0.33%

  • Rev 10Yr

    1.83%

  • Dil EPS 3Yr

    -5.81%

  • Dil EPS 5Yr

    2.11%

  • Dil EPS 10Yr

    -1.82%

  • Rev Fwd 2Yr

    5.3%

  • EBITDA Fwd 2Yr

    0.3%

  • EPS Fwd 2Yr

    7.78%

  • EPS LT Growth Est

    8.4%

Dividends

  • Yield

  • Payout

    53.4%

  • DPS

    £0.59

  • DPS Growth 3Yr

    -16.13%

  • DPS Growth 5Yr

    -10.01%

  • DPS Growth 10Yr

    -5.02%

  • DPS Growth Fwd 2Yr

    4.24%

Select a metric from the list below to chart it

Dec '14

Dec '15

Dec '16

Dec '17

Dec '18

Dec '19

Dec '20

Dec '21

Dec '22

Dec '23

LTM

Dec '24 (E)

Dec '25 (E)

Dec '26 (E)

Total Revenues

33,754

24,354

24,696

29,324

30,328

30,740

Total Revenues % Chg.

9.5%

-27.8%

1.4%

18.7%

3.4%

5.7%

Cost of Goods Sold, Total

10,792

7,321

8,033

9,407

8,388

8,400

Gross Profit

22,962

17,033

16,663

19,917

21,940

22,340

Selling General & Admin Expenses, Total

10,962

7,041

6,784

8,179

9,156

9,070

R&D Expenses

4,405

4,397

4,627

5,153

5,823

5,956

Other Operating Expenses

-606

-455

-382

-737

-1,442

-1,413

Other Operating Expenses, Total

14,761

10,983

11,029

12,595

13,537

13,613

Operating Income

8,201

6,050

5,634

7,322

8,403

8,727

Interest Expense, Total

-877

-844

-762

-819

-710

-675

Interest And Investment Income

79

26

13

62

108

111

Net Interest Expenses

-798

-818

-749

-757

-602

-564

Income (Loss) On Equity Invest.

74

33

33

-2

-5

-4

Other Non Operating Income (Expenses)

-12

-24

-6

-46

-75

-75

EBT, Excl. Unusual Items

7,465

5,241

4,912

6,517

7,721

8,084

Restructuring Charges

-1,110

-1,178

-424

-321

-382

-331

Gain (Loss) On Sale Of Investments

-14

-242

1

256

-121

-122

Gain (Loss) On Sale Of Assets

541

2,857

552

215

61

61

Asset Writedown

-83

-200

-347

-296

-398

-436

Legal Settlements

922

Other Unusual Items

-578

-1,308

-1,095

-1,665

-817

-1,744

EBT, Incl. Unusual Items

6,221

5,170

3,599

5,628

6,064

5,512

Income Tax Expense

953

67

83

707

756

754

Earnings From Continuing Operations

5,268

5,103

3,516

4,921

5,308

4,758

Earnings Of Discontinued Operations

876

1,069

10,495

Minority Interest

-623

-230

-200

-460

-380

-274

Net Income

4,645

5,749

4,385

14,956

4,928

4,484

Net Income to Common Incl Extra Items

4,645

5,749

4,385

14,956

4,928

4,484

Net Income to Common Excl. Extra Items

4,645

4,873

3,316

4,461

4,928

4,484

Total Shares Outstanding

3,962.6

3,984.8

4,006.9

4,034.3

4,056.3

4,078

Weighted Avg. Shares Outstanding

3,957.6

3,981

4,003

4,026

4,052

4,058.3

Weighted Avg. Shares Outstanding Dil

4,012.8

4,030

4,052

4,084

4,111

4,118

EPS

1.2

1.4

1.1

3.7

1.2

1.1

EPS Diluted

1.2

1.4

1.1

3.7

1.2

1.1

EBITDA

10,321

8,100

7,756

9,089

10,304

10,537

Effective Tax Rate

15.3%

1.3%

2.3%

12.6%

12.5%

13.7%